Prominent publications by MICHAEL SHECHTER

KOL Index score: 18000

BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore ...

Known for Odyssey Outcomes |  Coronary Syndrome |  Patients Alirocumab |  Controlled Trial |  Primary Endpoint
KOL Index score: 3840

BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.

OBJECTIVES: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute ...

Known for Cardiovascular Outcomes |  Acute Coronary |  Statin Treatment |  Mace Ldlc |  9 Inhibition
KOL Index score: 3754

OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.

RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients ...

Known for 2 Diabetes |  Levels Lipoproteina |  Acute Coronary Syndrome |  Proprotein Convertase |  Therapies Reduce
KOL Index score: 797
Known for Arterial Hypertension |  2018 Esc |  Esh Guidelines


MICHAEL SHECHTER: Influence Statistics

Sample of concepts for which MICHAEL SHECHTER is among the top experts in the world.
Concept World rank
elderly coronary #90
obesity societies #96

Key People For Odyssey Outcomes

Top KOLs in the world
Robert Pordy
acute coronary syndrome odyssey outcomes cardiovascular events
monoclonal antibodies acute coronary syndrome cardiovascular outcomes
Andreas Michael Zeiher
endothelial cells myocardial infarction heart failure
Robert A Harrington
acute coronary syndromes myocardial infarction glycoprotein iib
Gregory G Schwartz
acute coronary syndrome cardiovascular events odyssey outcomes
Robert Patrick Giugliano
atrial fibrillation myocardial infarction acute coronary


Concepts for whichMICHAEL SHECHTERhas direct influence:Odyssey outcomes,  Alirocumab treatment,  Placebo patients,  Patients alirocumab,  Incident type,  Patients prediabetes,  2 diabetes,  Type 2.


Concepts related to the work of other authors for whichfor which MICHAEL SHECHTER has influence:Blood pressure,  Cardiovascular disease,  Arterial hypertension,  Hypertensive patients,  Heart failure,  Diabetes mellitus,  Renal denervation.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Leviev Cardiothoracic and Vascular Center, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Israel.

FREE Custom List